Reuters
Published Mar 14, 2023 07:09PM ET
(Reuters) - Pfizer Inc (NYSE:PFE) said on Tuesday that the U.S. Food and Drug Administration had expanded the emergency use authorization (EUA) of the company and its partner BioNTech SE (NASDAQ:BNTX)'s bivalent COVID-19 vaccine as a single booster dose in certain children.
The amended authorization is for children six months through four years of age who have completed their initial three-dose vaccination with Pfizer's original shot.
In December, the U.S. health regulator had authorized Pfizer/BioNTech's updated shot as a third dose to those aged six months through four years, who have not completed their primary vaccination series or are yet to receive the third dose.
The health regulator's amended authorization is based on data from 60 children, from the expanded age group, who completed primary vaccination with three doses and received a booster shot of Pfizer/BioNTech, and showed an immune response to both the original SARS-CoV-2 virus strain and to Omicron BA.4/BA.5.
Shots for youngest children in the United States were only approved in June last year, making them the last group to become eligible for vaccination. Government data shows that only 2.7% children under the age of two and less than 5% of children aged two to four years who are eligible have completed their primary vaccination series as of Nov. 30, representing a slow uptake of the initial vaccine doses in young children.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.